FDA Finalizes Heart Safety Labels for Drugs – QTc Gets the Nod
Published Date: 12/3/2025
Notice
Summary
The FDA just released new guidance to help drug makers include important heart safety info (QTc interval) in their prescription drug and biological product labels. This update affects companies making non-heart rhythm drugs and helps them show this info clearly and correctly. The guidance is final as of December 3, 2025, so companies should start updating labels soon to stay on track and avoid delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
QTc Safety Info Added to Patient Labels
If you take a prescription drug or biological product that is not a heart-rhythm (antiarrhythmic) medicine, FDA's final guidance published December 3, 2025 recommends including clinically relevant heart rate–corrected QT (QTc) interval prolongation information in product labeling. The guidance specifically adds recommendations for including QTc information in FDA‑approved patient labeling and for updating QTc information in currently‑approved labeling.
Early QTc Assessment in Drug Development
The guidance recommends that applicants for most non‑antiarrhythmic drugs with systemic bioavailability assess effects on cardiac repolarization early in clinical development, including a clinical electrocardiographic (ECG) evaluation. The guidance states the QTc assessment in early development may inform the frequency and continuation of ECG monitoring in late‑phase clinical trials.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in